Search tips
Search criteria 


Logo of f1000medLatest ContentReportsReportsReports
F1000 Med Rep. 2010; 2: 76.
Published online 2010 October 21. doi:  10.3410/M2-76
PMCID: PMC2981191

Recent advances in the assessment and treatment of falls in Parkinson's disease


Falls are among the most incapacitating features of Parkinson's disease. Prevention of falls requires a systematic assessment of all contributing factors (with emphasis on freezing of gait and frontal executive dysfunction), and a multidisciplinary treatment approach tailored to the specific pathophysiology of falls for each individual patient.

Introduction and context

Falls are both common and debilitating in patients with Parkinson's disease (PD). They have devastating consequences for affected individuals, often leading to injuries, secondary immobility, and reduced quality of life. Survival is reduced once falls have occurred [1], although a recent report failed to identify a relationship between falls and mortality risk in PD [2]. Falls are also important for the public health system, as the costs associated with falls and fall-related injuries are enormous. A prospective 20-year follow-up of 136 patients with newly diagnosed PD confirmed the high prevalence of falls (87%) and resulting fractures (35%) [3].

For the management of falls in PD, it is important to appreciate the complex and multifactorial pathophysiology. Both balance deficits and gait disorders inherent to PD can obviously lead to falls. Environmental factors such as slippery floors, loose rugs, poor lighting, or inadequate footwear may also contribute. There is an increasing awareness that freezing of gait - a sudden and episodically occurring inability to generate effective forward stepping movements - is one of the leading causes of falls, presumably because patients are caught by surprise due to the often unexpected nature of freezing events [4,5]. Recent work has underscored the additional importance of cognitive impairment as a key factor contributing to both falls and freezing [6,7]; falls are an issue in demented patients in particular [8]. Possible explanations for this link include more prominent dopaminergic denervation of the caudate nucleus [9] or more generalized cholinergic dysfunction [10].

Preventing falls is generally perceived as being difficult, but is not impossible. Given the complex multifactorial nature of falls and the experience in elderly non-parkinsonian populations [11], a multidisciplinary approach appears preferable, but for patients with PD this strategy is not yet backed by scientific evidence. Crucial elements in the therapeutic approach include optimizing pharmacotherapy - increasing PD medication for dopa-sensitive signs, and stopping sedative drugs - and tailored physiotherapy, based on evidence-based practice guidelines.

Here, we highlight a few important new developments in this field.

Recent advances

Assessment of the patient with falls

Each patient deserves a careful and systematic approach to identify all contributing factors. The quest should not stop when one causative factor has been found because falls are typically multifactorial in origin. A recent prospective study in 101 patients with early-stage PD assessed how various measures could predict falls [12]. The best prediction was reached by combining disease-specific measures (such as PD severity and freezing of gait severity) with balance measures (such as the occurrence of symptomatic orthostatic hypotension, the Tinetti total score, and the extent of postural anterior-posterior sway). However, even this combination attained a sensitivity and specificity for predicting falls of only around 80%. Including cognitive measures that are more specific may further improve these predictive scores [13], but this remains to be examined.

Particular emphasis should be placed on testing for freezing of gait - using a series of provoking tests, including rapid 360 degree turns on the spot [14] - and for frontal executive dysfunction [7]. Specific attention should be paid to fear of renewed falling as this is common in PD [15]. Fear of falling is not only a risk factor for renewed falls [16], it may also lead to secondary immobilization with all its related adverse consequences [17].

Optimizing medication

Most balance deficits are resistant to dopaminergic medication. However, gait problems - including freezing of gait - can improve with dopaminergic medication, although doses that are higher or more frequent than those typically needed to increase hand functioning may be required [18]. Recent work points to a possible role for cholinesterase inhibitors in the treatment of gait and balance deficits, both in PD [19,20] and in Alzheimer's disease [21], given that many axial motor deficits may result from misbalance between central cholinergic and dopaminergic systems [10]. Sedative drugs should be stopped whenever possible.

Stereotactic deep brain surgery

It has become clear that stereotactic deep brain surgery should be reserved for patients whose gait and balance deficits are still levodopa-responsive pre-operatively. Several studies are comparing bilateral stimulation of two different targets, namely the subthalamic nucleus (STN) and the internal globus pallidus [22,23]. The initial results indicate that both approaches are effective in providing short-term relief of motor symptoms, but one study suggested internal globus pallidus stimulation may offer better long-term outcomes for gait and balance deficits [22]. This difference was not evident in the largest study, although falls after a 2-year follow-up tended to be more common after STN stimulation [23], but this requires more study. In particular, STN stimulation has been associated with a worsening of gait and balance deficits, not only in the immediate postoperative phase, but also several years after follow-up [22,24]. Adjusting the stimulation parameters (e.g., markedly lowering the stimulation frequency) may be helpful in such patients [25]. The pedunculopontine nucleus has been studied as a promising new target, specifically for gait and balance deficits, but so far the results have not been very impressive [26,27].


The evidence-based guidelines on physiotherapy for PD were recently updated [28], providing a menu of treatment modalities to improve mobility and reduce falls. Examples of evidence-based physiotherapy strategies include cueing techniques, cognitive movement strategies, and the use of exercise. Rhythmic auditory or visual cues can improve gait in PD, including freezing of gait [29,30]. New inventive cueing approaches include walking glasses with different patterns of visual and auditory stimulation [31] and mental singing while walking [32]. Another promising approach, especially for PD patients with freezing of gait, is the use of cycling, the skill for which can be remarkably preserved in some patients [33]. Evidence based mainly on the effects of cueing on laboratory measures of gait and balance remains; the challenge is to ascertain an enduring clinical improvement in daily life, including a reduction of falls. Fears that cues might worsen the tendency to fall - for example, by increasing overall mobility - have not been substantiated [29]. The same holds true for the effect of exercise. A systematic review concluded that exercise in patients with PD results in improvement in postural stability and balance task performance [34]. However, power and quality of exercise studies have hitherto been insufficient to make definitive recommendations. Future randomized controlled trials will look into the (cost) effectiveness of exercise to reduce falls [35,36].

There is a growing body of literature on the use of treadmill training for gait rehabilitation in patients with neurologic disorders in general and for patients with PD in particular. A recent Cochrane review concluded that treadmill training may help to improve gait akinesia in PD, but the effect on falls remains unclear [37]. It also remains uncertain how long any improvements induced by treadmill training may last.

Another interesting new development is the use of robotics, which can assist PD patients in making medio-lateral anticipatory weight shifts in preparation for taking a step [38]. The initial results are promising, and such new techniques now need to be implemented in situations that are more realistic to evaluate the clinical merits of these techniques in relation to everyday gait performance and falls.

Delivering such specific physiotherapy interventions to patients with PD likely requires trained expert physiotherapists. A large cluster-randomized trial showed that a community-based professional network with trained expert physiotherapists improved the quality of physiotherapy care and reduced health care costs, but without health benefits for patients [39].

Implications for clinical practice

Asking about falls and their impact on daily functioning should be a standard part of the evaluation of patients with PD. While awaiting further evidence, neurologists should consider installing a multidisciplinary team approach to tackle the vexing problem of falls in patients with PD. Management involves a systematic search for risk factors for falling, and a subsequent multifactorial approach aimed at eliminating or alleviating all patient-related and environmental risk factors for falling. Apart from optimizing dopaminergic medication, cholinergic therapies are now beginning to enter the field of play as well. Fear of falling must be addressed, and immobilization must be avoided as long as independent movements can still be made reasonably safely. The multidisciplinary team should ideally consist of trained and experienced professionals who treat large numbers of patients. Using this integrated approach, the goal should be to at least reduce falls or perhaps prevent them altogether, restore mobility and independence, and thereby help to maintain the quality of life for patients with PD.


This research was supported by the Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO or Netherlands Organization for Scientific Research) (016076352 to BB, 92003490 to AS) and by the Stichting Internationaal Parkinson Fonds (Parkinson Foundation International Fund).


Parkinson's disease
subthalamic nucleus


The electronic version of this article is the complete one and can be found at:


Competing Interests

The authors declare that they have no competing interests.


1. Wenning GK, Ebersbach G, Verny M, Chaudhuri KR, Jellinger K, Mckee A, Poewe W, Litvan I. Progression of falls in postmortem-confined parkinsonian disorders. Mov Disord. 1999;14:947–50. [PubMed]
2. Matinolli M, Korpelainen JT, Sotaniemi KA, Myllylä VV, Korpelainen R. Recurrent falls and mortality in Parkinson's disease: a prospective two-year follow-up study. Acta Neurol Scand. 2010 [Epub ahead of print] [PubMed]
3. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. Mov Disord. 2008;23:837–44. doi: 10.1002/mds.21956. [PubMed] [Cross Ref]Changes Clinical Practice
F1000 Factor 6.0 Must Read
Evaluated by Stewart Factor 11 Jul 2008
4. Bloem BR, Hausdorff JM, Visser JE, Giladi N. Falls and freezing in Parkinson's disease: a review of two interconnected, episodic phenomena. Mov Disord. 2004;19:871–84. doi: 10.1002/mds.20115. [PubMed] [Cross Ref]
5. Latt MD, Lord SR, Morris JG, Fung VS. Clinical and physiological assessments for elucidating falls risk in Parkinson's disease. Mov Disord. 2009;24:1280–9. doi: 10.1002/mds.22561. [PubMed] [Cross Ref] F1000 Factor 6.0 Must Read
Evaluated by David Williams 01 Sep 2009
6. Amboni M, Cozzolino A, Longo K, Picillo M, Barone P. Freezing of gait and executive functions in patients with Parkinson's disease. Mov Disord. 2008;23:395–400. doi: 10.1002/mds.21850. [PubMed] [Cross Ref]
7. Yogev-Seligmann G, Hausdorff JM, Giladi N. The role of executive function and attention in gait. Mov Disord. 2008;23:329–42. doi: 10.1002/mds.21720. [PMC free article] [PubMed] [Cross Ref]
8. Allan LM, Ballard CG, Rowan EN, Kenny RA. Incidence and prediction of falls in dementia: a prospective study in older people. PLoS One. 2009;4:e5521. doi: 10.1371/journal.pone.0005521. [PMC free article] [PubMed] [Cross Ref]
9. Bartels AL, de Jong BM, Giladi N, Schaafsma JD, Maguire RP, Veenma L, Pruim J, Balash Y, Youdim MB, Leenders KL. Striatal dopa and glucose metabolism in PD patients with freezing of gait. Mov Disord. 2006;21:1326–32. doi: 10.1002/mds.20952. [PubMed] [Cross Ref]
10. Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res. 2010 [Epub ahead of print] [PMC free article] [PubMed]
11. Gillespie LD, Gillespie WJ, Robertson MC, Lamb SE, Cumming RG, Rowe BH. Interventions for preventing falls in elderly people. Cochrane Database Syst Rev. 2009;2:CD000340. [PubMed]
12. Kerr GK, Worringham CJ, Cole MH, Lacherez PF, Wood JM, Silburn PA. Predictors of future falls in Parkinson disease. Neurology. 2010;75:116–24. doi: 10.1212/WNL.0b013e3181e7b688. [PubMed] [Cross Ref]
13. Thevathasan W, Aziz T. Predicting falls in Parkinson disease: a step in the right direction. Neurology. 2010;75:107–8. doi: 10.1212/WNL.0b013e3181e7b6b5. [PubMed] [Cross Ref]
14. Snijders AH, Nijkrake MJ, Bakker M, Munneke M, Wind C, Bloem BR. Clinimetrics of freezing of gait. Mov Disord. 2008;23(Suppl 2):S468-74. doi: 10.1002/mds.22144. [PubMed] [Cross Ref]
15. Thomas AA, Rogers JM, Amick MM, Friedman JH. Falls and the falls efficacy scale in Parkinson's disease. J Neurol. 2010;257:1124–8. doi: 10.1007/s00415-010-5475-x. [PubMed] [Cross Ref]
16. Mak MK, Pang MY. Fear of falling is independently associated with recurrent falls in patients with Parkinson's disease: a 1-year prospective study. J Neurol. 2009;256:1689–95. doi: 10.1007/s00415-009-5184-5. [PubMed] [Cross Ref]
17. Brozova H, Stochl J, Roth J, Ruzicka E. Fear of falling has greater influence than other aspects of gait disorders on quality of life in patients with Parkinson's disease. Neuro Endocrinol Lett. 2009;30:453–7. [PubMed]
18. Grimbergen YA, Speelman AD, van der Marck MA, Schoon Y, Bloem BR. Gait, postural instability and freezing. In: Lang AE, Olanow CW, Stocchi F, editors. The Non-motor and Non-dopaminergic Features of Parkinson's Disease. Hoboken, New Jersey: Blackwell; 2010. in press.
19. Bohnen NI, Müller ML, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, Albin RL. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology. 2009;73:1670–6. doi: 10.1212/WNL.0b013e3181c1ded6. [PMC free article] [PubMed] [Cross Ref] F1000 Factor 3.2 Recommended
Evaluated by Mark Hallett 16 Dec 2009, David Brooks 12 Feb 2010
20. Litvinenko IV, Odinak MM, Mogil’naya VI, Emelin AY. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial) Neurosci Behav Physiol. 2008;38:937–45. doi: 10.1007/s11055-008-9077-3. [PubMed] [Cross Ref]
21. Assal F, Allali G, Kressig RW, Herrmann FR, Beauchet O. Galantamine improves gait performance in patients with Alzheimer's disease. J Am Geriatr Soc. 2008;56:946–7. doi: 10.1111/j.1532-5415.2008.01657.x. [PubMed] [Cross Ref]
22. Moro E, Lozano AM, Pollak P, Agid Y, Rehncrona S, Volkmann J, Kulisevsky J, Obeso JA, Albanese A, Hariz MI, Quinn NP, Speelman JD, Benabid AL, Fraix V, Mendes A, Welter ML, Houeto JL, Cornu P, Dormont D, Tornqvist AL, Ekberg R, Schnitzler A, Timmermann L, Wojtecki L, Gironell A, Rodriguez-Oroz MC, Guridi J, Bentivoglio AR, Contarino MF, Romito L, et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord. 2010;25:578–86. [PubMed] F1000 Factor 6.0 Must Read
Evaluated by Daniel Tarsy 15 Mar 2010
23. Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, Marks WJ, Jr, Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein JM, Stoner G, Starr PA, Simpson R, Baltuch G, De Salles A, Huang GD, Reda DJ, CSP 468 Study Group Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med. 2010;362:2077–91. doi: 10.1056/NEJMoa0907083. [PubMed] [Cross Ref]Changes Clinical Practice
F1000 Factor 3.0 Recommended
Evaluated by Robert Ruff 09 Jun 2010
24. van Nuenen BF, Esselink RA, Munneke M, Speelman JD, van LT, Bloem BR. Postoperative gait deterioration after bilateral subthalamic nucleus stimulation in Parkinson's disease. Mov Disord. 2008;23:2404–6. doi: 10.1002/mds.21986. [PubMed] [Cross Ref]
25. Moreau C, Defebvre L, Destée A, Bleuse S, Clement F, Blatt JL, Krystkowiak P, Devos D. STN-DBS frequency effects on freezing of gait in advanced Parkinson disease. Neurology. 2008;71:80–4. doi: 10.1212/01.wnl.0000303972.16279.46. [PubMed] [Cross Ref]
26. Moro E, Hamani C, Poon YY, Al-Khairallah T, Dostrovsky JO, Hutchison WD, Lozano AM. Unilateral pedunculopontine stimulation improves falls in Parkinson's disease. Brain. 2010;133:215–24. doi: 10.1093/brain/awp261. [PubMed] [Cross Ref] F1000 Factor 3.2 Recommended
Evaluated by Peter Brown 18 Dec 2009, Kate Watkins 30 Dec 2009
27. Ferraye MU, Debû B, Fraix V, Goetz L, Ardouin C, Yelnik J, Henry-Lagrange C, Seigneuret E, Piallat B, Krack P, Le Bas JF, Benabid AL, Chabardès S, Pollak P. Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease. Brain. 2010;133:205–14. doi: 10.1093/brain/awp229. [PubMed] [Cross Ref] F1000 Factor 3.0 Recommended
Evaluated by Peter Brown 23 Oct 2009
28. Keus SH, Munneke M, Nijkrake MJ, Kwakkel G, Bloem BR. Physical therapy in Parkinson's disease: evolution and future challenges. Mov Disord. 2009;24:1–14. doi: 10.1002/mds.22141. [PubMed] [Cross Ref]
29. Nieuwboer A, Kwakkel G, Rochester L, Jones D, van Wegen E, Willems AM, Chavret F, Hetherington V, Baker K, Lim I. Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE trial. J Neurol Neurosurg Psychiatry. 2007;78:134–40. doi: 10.1136/jnnp.200X.097923. [PMC free article] [PubMed] [Cross Ref]
30. Lim I, van Wegen E, de Goede C, Deutekom M, Nieuwboer A, Willems A, Jones D, Rochester L, Kwakkel G. Effects of external rhythmical cueing on gait in patients with Parkinson's disease: a systematic review. Clin Rehabil. 2005;19:695–713. doi: 10.1191/0269215505cr906oa. [PubMed] [Cross Ref]
31. McAuley JH, Daly PM, Curtis CR. A preliminary investigation of a novel design of visual cue glasses that aid gait in Parkinson's disease. Clin Rehabil. 2009;23:687–95. doi: 10.1177/0269215509104170. [PubMed] [Cross Ref]
32. Satoh M, Kuzuhara S. Training in mental singing while walking improves gait disturbance in Parkinson's disease patients. Eur Neurol. 2008;60:237–43. doi: 10.1159/000151699. [PubMed] [Cross Ref]
33. Snijders AH, Bloem BR. Images in clinical medicine. Cycling for freezing of gait. N Engl J Med. 2010;362:e46. [PubMed]
34. Dibble LE, Addison O, Papa E. The effects of exercise on balance in persons with Parkinson's disease: a systematic review across the disability spectrum. J Neurol Phys Ther. 2009;33:14–26. [PubMed]
35. Canning CG, Sherrington C, Lord SR, Fung VS, Close JC, Latt MD, Howard K, Allen NE, O’Rourke SD, Murray SM. Exercise therapy for prevention of falls in people with Parkinson's disease: a protocol for a randomised controlled trial and economic evaluation. BMC Neurol. 2009;9:4. doi: 10.1186/1471-2377-9-4. [PMC free article] [PubMed] [Cross Ref]
36. van Nimwegen M, Speelman AD, Smulders K, Overeem S, Borm G, Backx F, Bloem BR, Munneke M. Rationale and design of the ParkFit study: a randomized controlled trial to increase physical activity in patients with Parkinson's disease. Mov Disord. 2009;24(Suppl 1):S284–5.
37. Mehrholz J, Friis R, Kugler J, Twork S, Storch A, Pohl M. Treadmill training for patients with Parkinson's disease. Cochrane Database Syst Rev. 2010;1:CD007830. [PubMed]
38. Mille ML, Hilliard MJ, Martinez KM, Simuni T, Zhang Y, Rogers MW. Short-term effects of posture-assisted step training on rapid step initiation in Parkinson's disease. J Neurol Phys Ther. 2009;33:88–95. [PubMed]
39. Munneke M, Nijkrake MJ, Keus SH, Kwakkel G, Berendse HW, Roos RA, Borm GF, Adang EM, Overeem S, Bloem BR, ParkinsonNet Trial Study Group Efficacy of community-based physiotherapy networks for patients with Parkinson's disease: a cluster-randomised trial. Lancet Neurol. 2010;9:46–54. doi: 10.1016/S1474-4422(09)70327-8. [PubMed] [Cross Ref]

Articles from F1000 Medicine Reports are provided here courtesy of Faculty of 1000 Ltd